Observational studyThe oncologist2026

Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancer.

Adam Brufsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.